CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Tarih

Yazarlar

Schnell, Oliver

Barnard\\-Kelly, Katharine

Battelino, Tadej

Ceriello, Antonio

Larsson, Helena Elding

Fernandez\\-Fernandez, Beatriz

Frias, Juan\\-Pablo

Gavin, James R.

Giorgino, Francesco

DOI No

10.1186/s12933-024-02180-8

Diğer Tanımlayıcı No

WOS:001334087200001

Yayınevi

Anahtar kelimeler

Cardiovascular disease, Chronic kidney disease, CGM, Diabetes, Finerenone, GLP\\-1 RA, Guidelines, Heart failure, MASLD, NAFLD, Obesity, SGLT2 inhibitor, Teplizumab

URI

https://openaccess.acibadem.edu.tr/handle/11443/5884

Koleksiyonlar

Tam öğe sayfası